Development of an integrated Prostate Cancer Research Information System

被引:55
作者
Oh, William K.
Hayes, Julia
Evan, Carolyn
Manola, Judith
George, Daniel J.
Waldron, Helen
Donovan, Meaghan
Varner, John
Orechia, John
Katcher, Beth
Lu, Diana
Nevins, Arthur
Wright, Renee L.
Tormey, Lauren
Talcott, James
Rubin, Mark A.
Loda, Massimo
Sellers, William R.
Richie, Jerome P.
Kantoff, Philip W.
Weeks, Jane
机构
[1] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Dept Informat Serv, Boston, MA 02115 USA
[4] Massachusetts Gen Hosp, Div Med Oncol, Boston, MA 02114 USA
[5] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[6] Brigham & Womens Hosp, Div Urol Surg, Boston, MA 02115 USA
[7] Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02115 USA
关键词
database; Gleason score; prostate-specific antigen;
D O I
10.3816/CGC.2006.n.019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In this article, we describe the design and implementation of a comprehensive prostate cancer database developed to collect, store, and access clinical, treatment, and outcomes data for research and clinical care. Patients and Methods: The Prostate Cancer Clinical Research Information System is a relational database. Data are entered from multiple sources, including medical records, institutional laboratory, patient registration, pharmacy systems, and clinician forms. The history, design, and operational characteristics of the database are described. Issues regarding necessary staffing and funding of databases are reviewed. Results: Four thousand two hundred forty-six patients have information in the Prostate Cancer Clinical Research Information System. Mean age of patients is 62 years, and 89% are white. Seventy-one percent of patients presented at diagnosis with T1 or T2 disease, and 78% had biopsy Gleason scores of <= 7, 8-10 in 18%. Median prostate-specific antigen level at diagnosis was 7 ng/mL, and 77% of patients presented with increased prostate-specific antigen as a trigger symptom. Sixty-four percent of patients presented to our clinic having had no previous treatment for prostate cancer. The majority of approached patients provided consent for collection of clinical data, blood, and tissue. Quality control assessments demonstrate high levels of concordance among data entry personnel. Conclusion: Clinical databases are difficult to implement and maintain; however, they represent a valuable resource, particularly when linked to blood and tissue banks. Elements needed for a successful clinical database include engagement of clinicians, utility for research, and the ability to integrate with legacy systems. As cancer centers develop such databases, lessons learned from each experience should be shared in order to optimize the process.
引用
收藏
页码:61 / 66
页数:6
相关论文
共 4 条
[1]   Cancer statistics, 2006 [J].
Jemal, A ;
Siegel, R ;
Ward, E ;
Murray, T ;
Xu, JQ ;
Smigal, C ;
Thun, MJ .
CA-A CANCER JOURNAL FOR CLINICIANS, 2006, 56 (02) :106-130
[2]   The CaPSURE database: A methodology for clinical practice and research in prostate cancer [J].
Lubeck, DP ;
Litwin, MS ;
Henning, JM ;
Stier, DM ;
Mazonson, P ;
Fisk, R ;
Carroll, PR .
UROLOGY, 1996, 48 (05) :773-777
[3]   Outcome research: prostate cancer databases [J].
Moul, JW .
UROLOGIC ONCOLOGY, 2002, 7 (01) :39-42
[4]   Prostate cancer in men age 50 years or younger: A review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database [J].
Smith, CV ;
Bauer, JJ ;
Connelly, RR ;
Seay, T ;
Kane, C ;
Foley, J ;
Thrasher, JB ;
Kusuda, L ;
Moul, JW .
JOURNAL OF UROLOGY, 2000, 164 (06) :1964-1967